Pharmabiz
 

TMR price cut data shows measures inadequate to make cancer drugs affordable, says CSO

Our Bureau, New Delhi, Saturday, October 31, 2026, 14:15 Hrs  [IST]

The Trade Margin Rationalisation (TMR) implementation by the National Pharmaceutical Pricing Authority (NPPA), shows that margin cuts alone will not lead to reduction in overall cancer care and measures including capping of cancer treatment charges are required for affordable access to anti-cancer medicines, according to Working Group on Access to Medicines and Treatments, a network of patients, activists and professionals focusing on affordable medicines in the country.
 
A detailed analysis of the 643 anti-cancer formulations listed out by the NPPA as revised MRP based on the TMR initiative, based on data submitted by the companies till October 23, by the Working Group shows that the MRP remains unchanged for the formulation from the originator company, while the same formulation from generic or biosimilar comparator has witnessed significant MRP reductions.
 
For instance, the Working Group says, that the bevacizumab 400 mg vial from Roche under the brand Avastin remains at Rs. 1,23,506, same as the MRP prior to TMR implementation, while Reliance's Bevacirel, with same combination and strength, underwent a price cut of 83.27% to Rs. 12,668 per vial from Rs. 75,718 per vial. Avastin’s revised 400 mg vial MRP is approximately 13.8 times Bevacizab’s listed 400 mg vial MRP.
 
Abbott Healthcare's Bevacizab 400 mg/16 ml vial price has been cut 86.26% from Rs. 65,205.09 to Rs. 8,956.75 per vial.
 
Similarly, the price of Pemetrexed, 500 mg vial, branded as Alimta from Eli Lilly has seen the price remain unchanged at Rs. 29,531.25, while the generic comparator Pemgem from Dr Reddy's has seen a price cut of 51.53% from Rs. 7,032 to Rs. 3,408.64 per unit.
 
"These findings demonstrate that substantial reductions in distribution margins can coexist with unchanged MRPs for expensive originator medicines. They are consistent with a limitation of TMR: a high manufacturer-level reference price can permit a high final MRP even when the distribution margin complies with the cap," said the Working Group.
 
The published list also does not disclose the product-level reference Price To Stockist/Price To Distributor (PTS/PTD), which is required to verify why each MRP remains unchanged. These products warrant disclosure of the calculations and an affordability review, it added.
 
Experts said that the margin cuts alone will not lead to a reduction in overall cancer care, and new and efficacious treatments are still out of reach. Single-source medicines need different policy intervention, such as public health safeguards in the Patents Act, including the Section 92 and 100, which are special provisions to override standard patent exclusivity for the benefit of public health.
 
The Working Group also opined that the cancer treatment charges should also be capped in order to make cancer treatment affordable and accessible to the patients.
 
The data released by the organisation shows that all the 17 entries in the list from AstraZeneca, all 14 entries from Novartis, all 12 entries from Roche, and all 10 entries from Eli Lilly remains unchanged, while all 40 entries from Samarth Life Sciences were subject to change in MRP, with almost 70.5% average price cut, all 23 entries from RPG Life Sciences (average 70.9% cut), all 25 entries from Reliance Life Sciences (average 69.6% cut), and 57 out of 59 entries from Hetero Healthcare (average 57.4% cut), through the TMR implementation.
 
Across 18 selected multinational companies with 122 entries, almost 90.1% remained unchanged with negligible unweighted average reduction of 1.3%, it added.
 
It also reveals that out of the 643 entries till October 28, a total of 484 entries witnessed price reduction, while 159 entries had no reduction. Around 204 entries out of the 643 had no reduction or a price cut of up to 10%, when 275 of the total entries saw reductions of above 50%, 124 witnessed reduction of over 70%, and five entries with reduction of over 90% in prices. The average reduction for the total 643 entries was 38.22%, with average reduction among entries which has witnessed price cut was at 50.78%, it added.
 
Thiotepa 100 mg injection from Samarth Life Sciences, under the brand Samtepa records the largest rupee reduction in this list till October 28, with reduction of Rs. 72,921.53 per listed vial, from Rs. 80,071.86 to Rs. 7,150.33.
 
Biological medicines also show substantial reductions, with Hertumab’s listed pack price falling by Rs. 64,358, while BevaciRel 400 mg falls by Rs. 63,050.
 
"These examples demonstrate the potential scale of relief when patients were previously paying close to the old MRP," it added.
 
These are announced MRP reductions effective from 9 November 2026. Actual financial relief will depend on the prices patients previously paid, existing discounts or assistance arrangements, quantities used and compliance by hospitals and pharmacies. The difference between old and revised MRP is a reduction in the listed maximum charge, not evidence that every patient previously paid the old MRP, said the organisation.
 
The NPPA, on October 17, announced that it has undertaken Trade Margin Rationalisation (TMR) of 137 identified non-scheduled anti-cancer drugs in public interest to address excessive trade margins, make cancer treatment more affordable, and improve access to anti-cancer medicines. The intervention is expected to bring down the MRP of the identified non-scheduled anti-cancer drugs by up to 70%, depending on their existing price structures.
 
The 137 identified non-scheduled anti-cancer drugs include Immunotherapy drugs used for treating over 20 type of cancers, Denosumab used by breast and prostate cancer patients, pegfilgrastim which is used to prevent neutropenia in cancer patients and Bevacizumab, which is the approved drug to treat colon, ovary and cervical cancer. With this notification, MRP of widely used anti-cancer drugs such as pembrolizumab, durvalumab and osimertinib is expected become more accessible for cancer patients, said the pricing authority.

 
[Close]